Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.39 |
| ▸ | PIK3CA known ✓ | P42336 | 1/20 | 0.38 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.37 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.38 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.38 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29955380 | 1.00 | CYP3A4 (0.46) | CYP3A4TDP1ALOX15CASP1CASP7 | |
| SCHEMBL56105 | 0.97 | CYP3A4 (0.47) | CYP3A4TDP1ALOX15CASP1CASP7 | |
| SCHEMBL29780861 | 0.97 | CYP3A4 (0.47) | CYP3A4TDP1ALOX15CASP1CASP7 | |
| Water SCHEMBL4437578 | 0.95 | CYP3A4 (0.45) | CYP3A4TDP1ALOX15CASP1CASP7 | |
| Alcohol SCHEMBL29246863 | 0.88 | ENPP2 (0.45) | CYP3A4TDP1ALOX15CASP1CASP7 | |
| Sulfuric Acid SCHEMBL17580241 | 0.86 | GAA (0.41) | CYP3A4TDP1ALOX15CASP1CASP7 | |
| SCHEMBL3324879 | 0.86 | ENPP2 (0.39) | CYP3A4TDP1ALOX15CASP1CASP7 | |
| SCHEMBL9811292 | 0.84 | MEN1 (0.39) | CYP3A4TDP1ALOX15CASP1CASP7 | |
| Bicarbonate SCHEMBL28659065 | 0.84 | ALDH1A1 (0.38) | CYP3A4TDP1ALOX15CASP1CASP7 | |
| SCHEMBL29384186 | 0.83 | ENPP2 (0.44) | ENPP2TSHRALDH1A1LIPGCA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115737535-A | Controllable degradable nano composite gel and preparation method and application thereof | 西北工业大学 | 2023-03-07 | — | — | CN | claimed |
| CN-115612054-A | Dynamic cross-linked polyurethane material and synthesis method thereof | 河南城建学院 | 2023-01-17 | — | — | CN | claimed |
| CN-114460310-A | Colored latex microsphere and preparation method and application thereof | 天津康博尔生物基因技术有限公司 | 2022-05-10 | — | — | CN | claimed |
| CN-111471036-B | Diamine monomer and preparation method thereof, polyimide and preparation method and application thereof | 中山大学 | 2021-06-01 | — | — | CN | claimed |
| CN-111471036-A | Diamine monomer and preparation method thereof, polyimide and preparation method and application thereof | 中山大学 | 2020-07-31 | — | — | CN | claimed |
| US-20250250272-A1 | Diamine Compound, Polyimide Acid, Polyimide, and Preparation Method Therefor and Use Thereof | BYD COMPANY LIMITED (CN) | 2025-08-07 | — | — | US | disclosed |
| US-12250880-B2 | Compounds for electronic devices | MERCK PATENT GMBH (DE) | 2025-03-11 | — | — | US | disclosed |
| CN-110678729-B | Catalyst for reversing formaldehyde adducts and crosslinking | 豪夫迈·罗氏有限公司 | 2023-04-11 | — | — | CN | disclosed |
| CN-115737535-A | Controllable degradable nano composite gel and preparation method and application thereof | 西北工业大学 | 2023-03-07 | — | — | CN | disclosed |
| CN-115737535-A | Controllable degradable nano composite gel and preparation method and application thereof | 西北工业大学 | 2023-03-07 | — | — | CN | disclosed |
| CN-115612054-A | Dynamic cross-linked polyurethane material and synthesis method thereof | 河南城建学院 | 2023-01-17 | — | — | CN | disclosed |
| CN-115192765-A | Adhesive and preparation method and application thereof | 南方医科大学 | 2022-10-18 | — | — | CN | disclosed |
| WO-2007039114-A1 | NOVEL NITROCATECHOL DERIVATIVES HAVING SELECTIN LIGAND ACTIVITY | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2006121528-A2 | RING CLOSING AND RELATED METHODS AND INTERMEDIATES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006107771-A2 | PYRAZOLO[3,4-c]QUINOLINES, PYRAZOLO[3,4-c]NAPHTHYRIDINES, ANALOGS THEREOF, AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
| WO-2006107753-A2 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
| WO-2006107851-A1 | 1-SUBSTITUTED PYRAZOLO (3,4-C) RING COMPOUNDS AS MODULATORS OF CYTOKINE BIOSYNTHESIS FOR THE TREATMENT OF VIRAL INFECTIONS AND NEOPLASTIC DISEASES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
| EP-1696912-A2 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M Innovative Properties Company (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20060100229-A1 | Pyrazolopyridines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2006-05-11 | — | — | US | disclosed |
| WO-2005079195-A2 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250250272-A1 | Diamine Compound, Polyimide Acid, Polyimide, and Preparation Method Therefor and Use Thereof | WEE1, WEE2, DDC | ADRA2C 4588/4885PIK3CA 1528/4885ADRA2B 4598/4885 |
| US-20060100229-A1 | Pyrazolopyridines and analogs thereof | IL4, IL2, IL4I1 | ADRA2C 254/4885PIK3CA 824/4885ADRA2B 756/4885 |
| US-12250880-B2 | Compounds for electronic devices | ETV6, CYP2C19, ESR1 | ADRA2C 2295/4885PIK3CA 3180/4885ADRA2B 3047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.